NEW YORK (GenomeWeb) – MDxHealth reported today that its third quarter revenues rose 122 percent, driven by a sharp increase in the number of payors issuing positive coverage decisions for its ConfirmMDx and SelectMDx prostate cancer tests.

For the three months ended Sept. 30, the Belgian molecular diagnostics company said revenues rose to $9.1 million from $4.1 million in Q3 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.